Lye Mun Tho

Lye Mun Tho

Auto-generated profile, based on publicly available information

Lye Mun Tho

28Oncology, Beacon Hospital Sdn Bhd, Petaling Jaya, Malaysia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2021 in Future Oncology
Verified
Journal Article
Open access
ESEgbert F Smit
Egbert F Smit
CDChristophe Dooms
Christophe Dooms
JRJo Raskin
Jo Raskin
Ernest NadalErnest Nadal
Ernest Nadal
LTLye M Tho
Lye M Tho
YWYI-LONG WU
YI-LONG WU
MET amplification (METamp), a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors, occurs in up to 30% of patients with non-small-cell lung cancer (NSCLC) progressing on first-line ... Plain language summary Osimertinib is used to treat a type of lung cancer that has specific changes (mutations) in a gene called EGFR. Although tumors will usually shrink (respond) during treatment...

1 July 2024 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
MPMAU-ERN POH
MAU-ERN POH
SBSivasubramaniam Balakrishnan
Sivasubramaniam Balakrishnan
STSin Nee Tan
Sin Nee Tan
MAMuhammad Adil Zainal Abidin
Muhammad Adil Zainal Abidin
CLChong Kin Liam
Chong Kin Liam
SHSoon Hin How
Soon Hin How
Background: Response rates of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC) to lower doses of osimertinib [20 mg once daily (OD) and 40 mg OD] are similar to those of the recommended dose of 80 mg OD, but there is a lack of real-world evidence on the effect of the lower doses of osimertinib on survival outcomes. We conducted this study to assess the efficacy and safety of lower osimertinib doses for patients with EGFR-mutated advanced NSCLC whose disease had progressed on earlier generation EGFR tyrosine kinase inhibitors (TKIs) in a real-world clinical practice. Methods: This multicenter, retrospective study included patients with EGFR-mutated advanced NSCLC treated with low doses of osimertinib after failing first- or second-generation EGFR TKIs due to acquired T790M mutation. Data on demographics, staging, treatment history, best overall response rate (ORR) based on RECIST 1.1, and adverse events (AEs) were collected from the patients’ case notes. Descriptive data were described in percentages and medians. Progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method. Results: Of the 22 patients studied [males =8 and females =14; Eastern Cooperative Oncology Group (ECOG) 1 or 2 =7 and ECOG 3 or 4 =15], 45.5% were on 40 mg OD, 31.8% were on 80 mg every other day (EOD), and 22.7% on 40 mg EOD. First-line EGFR TKIs used included afatinib, erlotinib, and gefitinib. The ORR with lower doses of second-line osimertinib was 77.3%. Overall, the median PFS was 10.0 months [95% confidence interval (CI): 8.6–11.4] and median OS was 13.0 months (95% CI: 9.4–16.6). In patients with ECOG 1 or 2, the median PFS was 18.0 months (95% CI: 5.8–30.2) and the median OS was not reached at the time of analysis. In patients with poor ECOG performance status of 3 and 4, good survival outcomes were also seen with a median PFS of 7.0 months (95% CI: 4.7–9.3) and median OS of 10.0 months (95% CI: 7.5–12.5). All AEs except one case of paronychia were Grade 1. There were no Grade 3 or 4 AEs. Conclusions: Treatment with low dose osimertinib demonstrated good efficacy and tolerability in EGFR-mutated advanced NSCLC patients who failed first-line treatment with first- or second-generation EGFR TKIs due to T790M mutation.

26 November 2025 in Lung Cancer
Verified
Journal Article
Open access
LWLin Wu
Lin Wu
JLJunling Li
Junling Li
CXChong-Rui Xu
Chong-Rui Xu
BBBivas Biswas
Bivas Biswas
SRSomnath Roy
Somnath Roy
YWYI-LONG WU
YI-LONG WU
Dacomitinib, a second-generation, irreversible tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), showed statistically significant progression-free survival improvement over gefitinib in patients with treatment-naive EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) in the phase 3 ARCHER 1050 study (NCT01774721). We report results from the final analysis of ARIA (NCT04609319), a noninterventional study of dacomitinib's real-world utilization and associated clinical outcomes in Asian patients with EGFR mutation-positive advanced NSCLC. This longitudinal, multicenter cohort study collected prospective and retrospective data from patients with EGFR mutation-positive locally advanced or metastatic NSCLC who were treated with first-line dacomitinib. Study objectives were to describe clinical and disease characteristics, therapeutic patterns of dacomitinib use, and clinical outcomes. 299 patients located in China (n = 261), India (n = 24), and Malaysia (n = 14) were enrolled and included in the analysis. Starting dose was 30 mg once daily in 159 (53.2 %) patients, 45 mg once daily in 138 (46.2 %), and other doses in 2 (0.7 %). As of May 28, 2024, 95 patients (31.8 %) had dose reductions, 47 (15.7 %) had dose increases, 41 (13.7 %) had dose interruptions, and 223 (74.6 %) had permanently discontinued dacomitinib. Median duration of treatment was 17.2 months (IQR, 19.2). Median time to treatment failure was 17.0 months (95 % CI, 14.5-19.8). Median progression-free survival was 20.1 months (95 % CI, 17.4-22.4). 148 (49.5 %) patients had treatment-related adverse events; most common were rash (n = 93 [31.1 %]), diarrhea (n = 81 [27.1 %]), and paronychia (n = 57 [19.1 %]). To our knowledge, ARIA is the largest real-world study of dacomitinib's efficacy and safety. Final analysis of this study showed substantial clinical efficacy of dacomitinib and revealed treatment patterns, such as starting dose, in the real world. Safety data were consistent with dacomitinib's known safety profile. These results support first-line dacomitinib use in Asian patients with EGFR mutation-positive advanced NSCLC. gov NCT04609319.

2 June 2026 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
BABoon Hong Ang
Boon Hong Ang
SYSook-Yee Yoon
Sook-Yee Yoon
JLJoanna Lim
Joanna Lim
NHNur Tiara Hassan
Nur Tiara Hassan
MTMei-Chee Tai
Mei-Chee Tai
STSoo Hwang Teo
Soo Hwang Teo
Background: Germline BRCA1/2 testing is recommended for all patients with ovarian cancer, as identifying pathogenic variants (PV) informs treatment and enables family cascade testing. However, in resource-limited settings, high testing costs often limit feasibility. An alternative approach is to use predictive models to prioritize patients at risk, optimizing resource allocation. Existing models are largely Western-derived; in Asian populations, models exist for breast cancer—not ovarian cancer. Methods: Using data from a multicenter study of 1,126 Asian patients with ovarian cancer (including 147 BRCA PV carriers), we developed models incorporating cancer history, clinicopathologic features, and reproductive factors to estimate the likelihood of carrying PVs. We assessed discrimination, calibration, and accuracy and compared genetic testing costs with a universal testing strategy. Results: Our final model demonstrated good calibration and strong discriminatory power, with an area under the curve of 0.80 (95% confidence interval, 0.74–0.87). Factors included in the model were age at diagnosis, ethnicity, personal and family cancer history, and clinicopathologic features. The model had 77% accuracy at the optimal threshold for testing compared with 13% accuracy with universal testing, reducing genetic testing costs from ∼USD4,371 to ∼USD1,974 per identified carrier. Notably, while maintaining 100% sensitivity, the model reduced testing by 15%, yielding potential savings of ∼USD68,182 per 800 patients each year. Conclusions: Targeted testing using a prediction model potentially offers a more efficient and scalable alternative when universal testing is not feasible, optimizing impact in resource-limited settings. Impact: This work supports more affordable and equitable BRCA testing pathways for Asian patients with ovarian cancer.